8-K: ImmixBio NXC-201 Shows 75% CR in AL Amyloidosis Trial

Immix Biopharma announced positive Phase 2 NXC-201 results for relapsed/refractory AL Amyloidosis, achieving a 75% complete response rate in the NEXICART-2 trial.

Summary

• Immix Biopharma announced positive Phase 2 NXC-201 results for relapsed/refractory AL Amyloidosis, presented at the American Society of Hematology (ASH) 2025 Annual Meeting.
• NXC-201 demonstrated a complete response (CR) rate of 75% (15 out of 20 patients) by independent review committee.
• Minimum residual disease (MRD) negativity in bone marrow for four out of five pending patients suggests a potential future CR rate of 95%.
• Downstream clinical improvement, including organ responses, was observed in 70% of evaluable patients (7 out of 10).
• The safety profile showed no neurotoxicity and only low-grade cytokine release syndrome (Grade 2 in 4 patients, Grade 1 in 11 patients) with a median duration of 1 day.
• All patients treated with NXC-201 had relapsed/refractory AL Amyloidosis organ involvement and were previously exposed to an anti-CD38 antibody and a proteasome inhibitor, with a median of 4 prior lines of therapy (range: 1-10).

Sentiment

Score: 9

Explanation: The filing reports exceptionally strong positive Phase 2 clinical trial results for NXC-201, demonstrating a high complete response rate and favorable safety profile in a disease with significant unmet medical need. The results are significantly better than current industry standards, positioning the company well for future regulatory submissions.

Positives

• Achieved a high complete response (CR) rate of 75% (15/20) in relapsed/refractory AL Amyloidosis patients.
• Potential for the CR rate to increase to 95% based on minimum residual disease (MRD) negativity in bone marrow for four out of five pending patients.
• Observed significant downstream clinical improvement, including organ responses, in 70% of evaluable patients (7/10).
• Demonstrated a favorable safety profile with no neurotoxicity and only low-grade cytokine release syndrome (median duration 1 day).
• NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
• The results significantly exceed typical CR rates of 10% or lower for current treatments in relapsed/refractory AL Amyloidosis, addressing a high unmet medical need.

Risks

• Further data from the ongoing Phase 2 clinical trials for CAR-T NXC-201 may not be favorably consistent with the data readouts to date.
• The Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 2 clinical trial.
• The Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates.
• Success in early phases of pre-clinical and clinical trials does not ensure later clinical trials will be successful.
• No drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product.
• The Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed.
• Other risks disclosed in the Company's Annual Report on Form 10-K filed with the SEC on March 25, 2025, and other periodic or current reports subsequently filed with the SEC.

Future Outlook

Immix Biopharma plans for the NEXICART-2 final readout and Biologics License Application (BLA) submission in 2026, aiming to deliver NXC-201 as a potentially firstand best-in-class therapy for relapsed/refractory AL Amyloidosis. The company anticipates a potential increase in the complete response rate to 95% based on current minimum residual disease (MRD) negativity data.

Management Comments

• "We are thrilled to see complete response rates continue to improve in NEXICART-2. These excellent results demonstrate the potential of NXC-201 to address the significant unmet medical need in relapsed/refractory AL Amyloidosis." Ilya Rachman, MD, PhD, Chief Executive Officer.
• "This exciting Phase 2 milestone brings us one step closer to delivering this promising therapy to patients upon planned BLA submission in 2026." Gabriel Morris, Chief Financial Officer.

Industry Context

AL Amyloidosis is a devastating disease where the immune system produces toxic light chains, leading to organ failure. The number of patients with relapsed/refractory AL Amyloidosis in the U.S. is estimated to be growing at 12% per year, reaching approximately 38,500 patients in 2026. The overall Amyloidosis market is substantial, projected to grow from $3.6 billion in 2017 to $6 billion in 2025, indicating a high unmet medical need and significant market opportunity for effective therapies like NXC-201.

Comparison to Industry Standards

• NXC-201's observed complete response (CR) rate of 75% significantly surpasses typical CR rates of 10% or lower for current treatments in relapsed/refractory AL Amyloidosis, as cited by Zanwar, et al 2024.
• The potential for a 95% CR rate, based on MRD negativity, further highlights NXC-201's superior efficacy compared to existing therapies.
• The favorable safety profile, with no neurotoxicity and only low-grade cytokine release syndrome, is a positive differentiator in the CAR-T therapy landscape, where such side effects can be a concern.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for a first-in-class therapy, and clear advancement towards BLA submission, which could significantly increase company valuation.
• Patients with AL Amyloidosis: Significant positive impact as NXC-201 offers a potentially highly effective treatment option with a favorable safety profile for a devastating disease with high unmet medical need.
• Medical Community: Provides new, promising data for the treatment of relapsed/refractory AL Amyloidosis, potentially influencing future treatment paradigms and offering a new therapeutic avenue.
• Employees: Positive impact from successful clinical development and progress towards commercialization, potentially leading to increased job security and growth opportunities.

Next Steps

• NEXICART-2 final readout.
• Biologics License Application (BLA) submission for NXC-201 in 2026.
• Continue the NEXICART-2 multi-site U.S. Phase 2 clinical trial (NCT06097832), which is expected to enroll 40 patients.
• Advance to registration-enabling studies for CAR-T NXC-201.

Key Dates

Recommendation

The Phase 2 results for NXC-201 in relapsed/refractory AL Amyloidosis are exceptionally strong, demonstrating a 75% complete response rate (with potential for 95%) which is significantly superior to the 10% or lower rates of current treatments. The favorable safety profile (no neurotoxicity, low-grade CRS) further enhances its appeal. This data positions NXC-201 as a potential firstand best-in-class therapy in a market with high unmet medical need and substantial growth. The planned BLA submission in 2026 indicates a clear path to market. While risks inherent to drug development exist, the current data provides a compelling investment thesis for a strong buy, anticipating significant future value creation.

Keywords

Immix Biopharma, IMMX, NXC-201, CAR-T, AL Amyloidosis, relapsed/refractory, NEXICART-2, Phase 2, clinical trial, complete response, ASH 2025, biotechnology, oncology, hematology, FDA RMAT, Orphan Drug Designation